Advanced proliferative diabetic retinopathy and macular edema in acromegaly: a case report and literature review.

Acromegaly Growth hormone Insulin-like growth factor 1 Proliferative diabetic retinopathy Vascular endothelial growth factor

Journal

Diabetology international
ISSN: 2190-1678
Titre abrégé: Diabetol Int
Pays: Japan
ID NLM: 101553224

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 07 10 2021
accepted: 13 01 2022
entrez: 13 6 2022
pubmed: 14 6 2022
medline: 14 6 2022
Statut: epublish

Résumé

We describe the multimodal management of a patient with proliferative diabetic retinopathy and diabetic macular edema associated with active acromegaly. A 61-year-old Japanese female who had had type 2 diabetic mellitus for > 10 years complained of deteriorated eyesight. She had distinct acromegalic features, and her visual acuity was 0.05 (right) and 0.4 (left) because of sub-capsular cataracts and proliferative diabetic retinopathy with macular edema. Anti-vascular endothelial growth factor treatments, cataract surgeries and retinal direct laser photocoagulation were performed together with gradual glycemic control with basal insulin to prevent worsening of the visual impairment. She was given an injection of a long-acting somatostatin analog (octreotide LAR) and began taking three bolus mealtime insulin shots with basal insulin beginning 1 month before undergoing a trans-sphenoidal adenomectomy. After this successful surgery, her blood glucose levels immediately decreased, and the rapid-acting insulin at mealtimes was discontinued with the observation of normal growth hormone and insulin-like growth factor (IGF)-1 levels, suggesting that her acromegaly was in remission. Her visual acuity improved without a worsening of diabetic retinopathy. Since the increased IGF-1 production in systemic circulation and local vitreous fluids may be one of the aggravating factors for diabetic retinopathy, our patient's acromegaly complicated with severe retinopathy presented an opportunity for multimodal management in close collaboration with an ophthalmologist, neurosurgeon, and endocrinologist. Our literature review revealed that the estimated prevalence of diabetic retinopathy in cases of acromegaly associated with diabetes mellitus is 12.5-42.9%.

Identifiants

pubmed: 35693995
doi: 10.1007/s13340-022-00571-4
pii: 571
pmc: PMC9174379
doi:

Types de publication

Case Reports

Langues

eng

Pagination

575-579

Informations de copyright

© The Japan Diabetes Society 2022.

Déclaration de conflit d'intérêts

Conflict of interestNone of the authors have any potential conflicts of interest associated with this research.

Références

Nat Rev Dis Primers. 2019 Mar 21;5(1):20
pubmed: 30899019
Indian J Endocrinol Metab. 2014 May;18(3):407-9
pubmed: 24944939
Horm Res. 2007;67(2):67-72
pubmed: 17028441
J Clin Invest. 2004 Apr;113(8):1149-57
pubmed: 15085194
Science. 1997 Jun 13;276(5319):1706-9
pubmed: 9180082
J Clin Endocrinol Metab. 1998 Jul;83(7):2380-3
pubmed: 9661613
Diabetes Care. 2000 Jan;23(1):80-3
pubmed: 10857973
Ophthalmologica. 1978;176(2):74-80
pubmed: 634558
Curr Med Chem. 2006;13(27):3307-17
pubmed: 17168853
Diabetes Care. 2000 Apr;23(4):504-9
pubmed: 10857943
Orbit. 2002 Jun;21(2):161-7
pubmed: 12029573
Nat Med. 1999 Dec;5(12):1390-5
pubmed: 10581081
Pituitary. 2014 Feb;17(1):81-9
pubmed: 23446424
Eur J Endocrinol. 2020 Mar;182(3):293-302
pubmed: 31917679
Expert Opin Investig Drugs. 2007 Jan;16(1):73-82
pubmed: 17155855
J Chin Med Assoc. 2018 Mar;81(3):230-235
pubmed: 29198552
Diabetes. 1986 Apr;35(4):416-20
pubmed: 2420665
Intern Med J. 2002 Jan-Feb;32(1-2):52-4
pubmed: 11783677
ISRN Ophthalmol. 2013 Jan 15;2013:343560
pubmed: 24563789
Horm Metab Res. 2001 May;33(5):300-6
pubmed: 11440277
Pharmacol Ther. 2009 Jun;122(3):324-33
pubmed: 19351548
Arch Intern Med. 1981 Nov;141(12):1625-7
pubmed: 7305571
Endocrine. 2018 Apr;60(1):1-3
pubmed: 29464407
Oman J Ophthalmol. 2010 May;3(2):96-7
pubmed: 21217906
Lancet. 2010 Jul 10;376(9735):124-36
pubmed: 20580421
Br J Ophthalmol. 1999 May;83(5):629-30
pubmed: 10917684

Auteurs

Akiko Yuno (A)

Department of Endocrinology and Metabolism, Kin-Ikyo Chuo Hospital, 9-1 Higashi Naebo 5-jo 1-chome, Higashi-ku, Sapporo, Hokkaido 007-8505 Japan.

Akemi Ikota (A)

Department of Endocrinology and Metabolism, Kin-Ikyo Chuo Hospital, 9-1 Higashi Naebo 5-jo 1-chome, Higashi-ku, Sapporo, Hokkaido 007-8505 Japan.

Shigeki Koizumi (S)

Department of Endocrinology and Metabolism, Kin-Ikyo Chuo Hospital, 9-1 Higashi Naebo 5-jo 1-chome, Higashi-ku, Sapporo, Hokkaido 007-8505 Japan.

Yasuo Mashio (Y)

Department of Endocrinology and Metabolism, Kin-Ikyo Chuo Hospital, 9-1 Higashi Naebo 5-jo 1-chome, Higashi-ku, Sapporo, Hokkaido 007-8505 Japan.

Hiroko Imaizumi (H)

Department of Ophthalmology, Sapporo City General Hospital, Sapporo, 060-8604 Japan.

Yutaka Sawamura (Y)

Sawamura Neurosurgery Clinic, Sapporo, 060-0807 Japan.

Akira Shimatsu (A)

Advanced Medical Care Center, Omi Medical Center, Kusatsu, 525-8585 Japan.

Classifications MeSH